|
May 23
|
Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025
|
|
May 22
|
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
|
|
May 20
|
Kura Oncology to Participate in Three Upcoming Investor Conferences
|
|
May 14
|
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
|
|
Mar 7
|
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|